Core Viewpoint - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of +80.51% compared to a loss of $0.44 per share a year ago [1][2] Financial Performance - The company posted revenues of $290.38 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.21% and showing an increase from $252.45 million in the same quarter last year [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus revenue estimates four times [2] Stock Performance - Shares of Tandem Diabetes Care have declined approximately 13.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.45 on revenues of $249.96 million, and for the current fiscal year, it is -$0.99 on revenues of $1.1 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock performance [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Integer (ITGR) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.62%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.68 per share when it actually produced earnings of $1.79, delivering a surprise of +6.55%.Over the last four q ...

Core Viewpoint - Masimo (MASI) shares experienced a significant increase of 34.2% to close at $174.69, driven by a definitive acquisition agreement with Danaher Corporation valued at $180 per share, totaling approximately $9.9 billion [1][2]. Company Summary - The acquisition of Masimo by Danaher Corporation is an all-cash transaction, with completion expected in the second half of 2026, pending regulatory approvals and customary closing conditions [2]. - Masimo is projected to report quarterly earnings of $1.43 per share, reflecting a year-over-year decline of 20.6%, with revenues anticipated at $409.06 million, down 31.9% from the previous year [3]. - The consensus EPS estimate for Masimo has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Masimo is categorized under the Zacks Medical - Instruments industry, where UFP Technologies (UFPT) is another player, closing at $246.13 with a recent return of -5.7% over the past month [5]. - UFP Technologies has a consensus EPS estimate of $2.26, unchanged over the past month, representing an 8.1% decline from the previous year [6].

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.77%. A quarter ago, it was expected that this medical device maker would post earnings of $0.16 per share when it actually produced earnings of $0.36, delivering a surprise of +125%.Over the last four ...

Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.47%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.27 per share when it actually produced a loss of $0.16, delivering a surprise of +40.74%.Over the last four quarters, the com ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Compass Therapeutics, Inc. (CMPX) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Compass Therapeutics, Inc. is one of 925 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Z ...

分组1 - Pacific Biosciences reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.19, representing an earnings surprise of +36.84% [1] - The company posted revenues of $44.65 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 9.42%, compared to $39.22 million in the same quarter last year [2] - The stock has underperformed the market, losing about 1.6% since the beginning of the year, while the S&P 500 gained 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $42 million, and for the current fiscal year, it is -$0.57 on revenues of $177.35 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +21.43%. A quarter ago, it was expected that this biological medical device maker would post earnings of $0.14 per share when it actually produced earnings of $0.16, delivering a surprise of +14.29%.Over the last four q ...

Core Viewpoint - Inogen (INGN) shares experienced a significant increase of 6.6% to close at $6.13, driven by strong trading volume and a positive preliminary revenue update indicating steady growth and improved profitability [1][2]. Financial Performance - Inogen reported estimated fourth-quarter 2025 revenue of approximately $82 million, reflecting a year-over-year increase of about 2% [2][3]. - The full-year revenue for 2025 is projected to be around $349 million, indicating an annual growth rate of 4% [2]. - The company is expected to report a quarterly loss of $0.36 per share, which represents a year-over-year change of +12.2% [3]. Profitability and Operational Efficiency - Management indicated that Inogen is on track to achieve positive adjusted EBITDA for the full year of 2025, highlighting improvements in operating leverage, cost controls, and financial discipline [2]. Market Sentiment and Stock Performance - Despite the recent rise in stock price, the consensus EPS estimate for the upcoming quarter has been revised 5.3% lower over the last 30 days, which may indicate potential challenges ahead [5]. - The stock currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks in the same industry [6]. Industry Comparison - Inogen operates within the Zacks Medical - Instruments industry, where another company, Lucid Diagnostics Inc. (LUCD), saw a slight decline of 0.8% in its last trading session [6]. - Lucid Diagnostics has a consensus EPS estimate of -$0.07 for its upcoming report, reflecting a year-over-year change of +63.2% [7].

分组1 - Electromed, Inc. reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, and showing an increase from $0.22 per share a year ago, resulting in an earnings surprise of +20.76% [1] - The company achieved revenues of $18.9 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.40%, and up from $16.25 million year-over-year [2] - Electromed has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has underperformed the market, losing about 5.2% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $17.54 million, and for the current fiscal year, it is $1.07 on revenues of $71.61 million [7] - The Medical - Instruments industry, to which Electromed belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]